Hjem › Kastrasjonsresistent prostatakreft › California › Los Angeles
Kliniske studier for Kastrasjonsresistent prostatakreft i Los Angeles, CA
8 studier for Kastrasjonsresistent prostatakreft søker deltakere på steder i og rundt Los Angeles (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RekruttererFase 3
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 3
- USC Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 1
- START Los Angeles, Los Angeles
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RekruttererFase 1/2
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RekruttererFase 1/2
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RekruttererFase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
RekruttererFase 1
- The Angeles Clinic and Research Institute, Los Angeles
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RekruttererFase 4
- VA Greater Los Angeles Healthcare System, Los Angeles
Kastrasjonsresistent prostatakreft-studier i andre byer
- New York City, NY7 studier
- Seattle, WA6 studier
- Houston, TX6 studier
- Boston, MA5 studier
- Philadelphia, PA4 studier
- Pittsburgh, PA4 studier
- Queens, NY4 studier
- Mountain View, CA3 studier
- Minneapolis, MN3 studier
- Myrtle Beach, SC3 studier
- San Diego, CA3 studier
- Metairie, LA3 studier
Andre studier i Los Angeles
- Ikke-småcellet lungekreft87 studier
- Kreft (alle typer)74 studier
- Brystkreft73 studier
- Prostatakreft61 studier
- Kolorektal kreft59 studier
- Metastatisk kreft57 studier
- Eggstokkreft50 studier
- Lungekreft45 studier
- Plateepitelcancer i hode og hals42 studier
- Pankreaskreft35 studier
- Endometriekreft34 studier
- Melanom34 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.